12/7/2009
Celator^® Pharmaceuticals presents interim data from Phase 2 study of CPX-351 in newly diagnosed AML at American Society of Hematology Meeting

10/12/2009
Celator^® Pharmaceuticals completes enrollment early in Phase 2 study of CPX-351 in newly diagnosed AML

9/3/2009
Celator^® Pharmaceuticals to present at Thomas Weisel Partners 2009 Healthcare Conference

6/8/2009
Celator^® Pharmaceuticals presents data on the activity of CPX-351 against leukemia at the European Hematology Association Congress

5/21/2009
Celator^® Pharmaceuticals initiates research agreement with Cephalon, Inc.

5/13/2009
Celator^® Pharmaceuticals to present at 2009 BIO International Convention

4/22/2009
Celator^® Pharmaceuticals presents new data on CPX-351 and CPX-1 at the American Association for Cancer Research

3/26/2009
Celator^® Pharmaceuticals to present at Future Leaders in the Biotech Industry conference

3/10/2009
Celator^® Pharmaceuticals enrolls first patient in its Phase 2 study of CPX-351 in acute myeloid leukemia in first relapse

1/22/2009
The Leukemia & Lymphoma Society^® and Celator^® Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML

1/08/2009
Celator^® Pharmaceuticals to present at Biotech Showcase 2009